Rukunuzzaman M, Karim M B
Dr Md Rukunuzzaman, Associate Professor, Department of Paediatric Gastroenterology and Nutrition, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; E-mail:
Mymensingh Med J. 2015 Jul;24(3):649-56.
Hepatitis B Virus (HBV) infection is prevalent worldwide. The prevalence is lowest (0.2-0.5%) in countries having high standard of living. About 10 million people are chronically infected with HBV in Bangladesh and it is possible that most infections occur during childhood. Overall prevalence is about 3% in Bangladesh. Perinatal transmission is more common in hyper-endemic areas of South East Asia. Chronic hepatitis B infection evolves through five phases. Most of the children belong to immune tolerant phase. About 57% patients of chronic hepatitis B are asymptomatic. Treatment of chronic hepatitis B is difficult. Decision regarding when, whom and how to treat in children is complex. Moreover, there are only limited drugs that can be used in treating chronic hepatitis B in children. Goal of therapy are to reduce viral replication, to minimize liver injury, to reduce consequence of liver injury like cirrhosis, hepatocellular carcinoma and to reduce infectivity of HBV. Treatment should be considered in chronic hepatitis B if patient have persistently elevated ALT of more than twice normal and evidence of viral replication. There are some special circumstances where treatment of chronic hepatitis B can be given in absence of standard criteria. These conditions are cirrhosis, chemotherapy, immunosuppression, presence of co-infection (HBV-HIV), family history of HCC and pregnant women with high viral load. Sero-conversion occurs in about 17-32% cases if treated with oral nucleot(s)ide analogue and in about 58% cases if treated with interferon. These expensive drugs with limited treatment success are not suitable for the people of Bangladesh. Therefore, risk factors identification and prevention of HBV infection is the logical and rational approach for a country like Bangladesh. Vaccination against HBV play central role in preventing infection. HBV vaccine has been incorporated in EPI schedule since 2004 in Bangladesh. Immunoprophylaxis of babies of HBsAg positive mother and post exposure prophylaxis are effective ways of prevention.
乙型肝炎病毒(HBV)感染在全球范围内普遍存在。在生活水平高的国家,其流行率最低(0.2 - 0.5%)。孟加拉国有约1000万人慢性感染HBV,且大多数感染可能发生在儿童时期。孟加拉国的总体流行率约为3%。围产期传播在东南亚高流行地区更为常见。慢性乙型肝炎感染经历五个阶段。大多数儿童处于免疫耐受期。约57%的慢性乙型肝炎患者无症状。慢性乙型肝炎的治疗很困难。关于儿童何时、对谁以及如何治疗的决策很复杂。此外,可用于治疗儿童慢性乙型肝炎的药物有限。治疗目标是减少病毒复制、将肝损伤降至最低、减少肝损伤后果如肝硬化、肝细胞癌,并降低HBV的传染性。如果患者谷丙转氨酶(ALT)持续升高超过正常两倍且有病毒复制证据,则应考虑对慢性乙型肝炎进行治疗。在一些特殊情况下,即使没有标准标准也可对慢性乙型肝炎进行治疗。这些情况包括肝硬化、化疗、免疫抑制、合并感染(HBV - HIV)、肝细胞癌家族史以及高病毒载量的孕妇。如果用口服核苷(酸)类似物治疗,血清学转换发生率约为17 - 32%;如果用干扰素治疗,发生率约为58%。这些治疗成功率有限的昂贵药物不适合孟加拉国人民。因此,对于孟加拉国这样的国家,识别危险因素和预防HBV感染是合理且合乎逻辑的方法。乙肝疫苗接种在预防感染中起核心作用。自2004年以来,乙肝疫苗已被纳入孟加拉国的扩大免疫规划(EPI)。对乙肝表面抗原(HBsAg)阳性母亲的婴儿进行免疫预防和暴露后预防是有效的预防方法。